In-Depth Comparison of Adeno-Associated Virus Containing Fractions after CsCl Ultracentrifugation Gradient Separation.

CsCl ultracentrifugation gradient Illumina sequencing analytical methods analytical ultracentrifugation (AUC) digital droplet PCR (ddPCR) recombinant adeno-associated viruses (rAAVs) size-exclusion chromatography coupled with multi-angle light scattering (SEC-MALS) transmission electron microscopy (TEM)

Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
31 Jul 2024
Historique:
received: 26 04 2024
revised: 24 07 2024
accepted: 25 07 2024
medline: 1 9 2024
pubmed: 31 8 2024
entrez: 29 8 2024
Statut: epublish

Résumé

Recombinant adeno-associated viruses (rAAVs) play a pivotal role in the treatment of genetic diseases. However, current production and purification processes yield AAV-based preparations that often contain unwanted empty, partially filled or damaged viral particles and impurities, including residual host cell DNA and proteins, plasmid DNA, and viral aggregates. To precisely understand the composition of AAV preparations, we systematically compared four different single-stranded AAV (ssAAV) and self-complementary (scAAV) fractions extracted from the CsCl ultracentrifugation gradient using established methods (transduction efficiency, analytical ultracentrifugation (AUC), quantitative and digital droplet PCR (qPCR and ddPCR), transmission electron microscopy (TEM) and enzyme-linked immunosorbent assay (ELISA)) alongside newer techniques (multiplex ddPCR, multi-angle light-scattering coupled to size-exclusion chromatography (SEC-MALS), multi-angle dynamic light scattering (MADLS), and high-throughput sequencing (HTS)). Suboptimal particle separation within the fractions resulted in unexpectedly similar infectivity levels. No single technique could simultaneously provide comprehensive insights in the presence of both bioactive particles and contaminants. Notably, multiplex ddPCR revealed distinct vector genome fragmentation patterns, differing between ssAAV and scAAV. This highlights the urgent need for innovative analytical and production approaches to optimize AAV vector production and enhance therapeutic outcomes.

Identifiants

pubmed: 39205208
pii: v16081235
doi: 10.3390/v16081235
pii:
doi:

Substances chimiques

Cesium 1KSV9V4Y4I
cesium chloride GNR9HML8BA
Chlorides 0

Types de publication

Journal Article Comparative Study

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Slovenian Research Agency
ID : P4-0407; L4-3180; 1000-20-0105; 1000-21-0105; S-ZDR/22-27/0105

Auteurs

Mojca Janc (M)

National Institute of Biology, Večna pot 121, 1000 Ljubljana, Slovenia.
Jožef Stefan International Postgraduate School, Jamova cesta 39, 1000 Ljubljana, Slovenia.

Kaja Zevnik (K)

National Institute of Biology, Večna pot 121, 1000 Ljubljana, Slovenia.

Ana Dolinar (A)

National Institute of Biology, Večna pot 121, 1000 Ljubljana, Slovenia.

Tjaša Jakomin (T)

National Institute of Biology, Večna pot 121, 1000 Ljubljana, Slovenia.

Maja Štalekar (M)

National Institute of Biology, Večna pot 121, 1000 Ljubljana, Slovenia.

Katarina Bačnik (K)

National Institute of Biology, Večna pot 121, 1000 Ljubljana, Slovenia.

Denis Kutnjak (D)

National Institute of Biology, Večna pot 121, 1000 Ljubljana, Slovenia.

Magda Tušek Žnidarič (MT)

National Institute of Biology, Večna pot 121, 1000 Ljubljana, Slovenia.

Lorena Zentilin (L)

International Center for Genetic Engineering and Biotechnology, Area Science Park, Padriciano 99, 34149 Trieste, Italy.

Dmitrii Fedorov (D)

Department of Bioproducts and Biosystems, Aalto University, P.O. Box 16100, 00076 Aalto, Finland.
Center of Excellence in Life-Inspired Hybrid Materials (LIBER) Aalto University, P.O. Box 16100, 00076 Aalto, Finland.

David Dobnik (D)

National Institute of Biology, Večna pot 121, 1000 Ljubljana, Slovenia.
Niba Labs d.o.o., Litostrojska cesta 52, 1000 Ljubljana, Slovenia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH